Lupin#39;s Goa facility may face regulatory action, says USFDA

The company has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at its Goa facility between January 28 to February 8 as Official Action Indicated (OAI), Lupin said in a regulatory filing.

from Moneycontrol Business News http://bit.ly/2Z0UEHU